Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
- 1 November 2019
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 30 (11), 1784-1795
- https://doi.org/10.1093/annonc/mdz298
Abstract
Background: In early breast cancer (BC), there has been a trend to escalate endocrine therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus CT on the quality of life (QoL) of early BC patients is unknown. Here, we characterize the independent contribution of ET and CT on patient-reported outcomes (PROs) at 2 years after diagnosis. Patients and methods: We prospectively collected PROs in 4262 eligible patients using the European Organization for Research and Treatment of Cancer QLQ-C30/BR23 questionnaires inside CANTO trial (NCT01993498). The primary outcome was the C30 summary score (C30-SumSc) at 2 years after diagnosis. Results: From eligible patients, 37.2% were premenopausal and 62.8% postmenopausal; 81.9% received ET and 52.8% CT. In the overall cohort, QoL worsened by 2 years after diagnosis in multiple functions and symptoms; exceptions included emotional function and future perspective, which improved over time. ET (P-int = 0.004), but not CT (P-int = 0.924), had a persistent negative impact on the C30-SumSc. In addition, ET negatively impacted role and social function, pain, insomnia, systemic therapy side-effects, breast symptoms and further limited emotional function and future perspective recovery. Although CT had no impact on the C30-SumSc at 2-years it was associated with deteriorated physical and cognitive function, dyspnea, financial difficulties, body image and breast symptoms. We found a differential effect of treatment by menopausal status; in premenopausal patients, CT, despite only a non-significant trend for deteriorated C30-SumSc (P-int = 0.100), was more frequently associated with QoL domains deterioration than ET, whereas in postmenopausal patients, ET was more frequently associated with QoL deterioration, namely using the C30-SumSc (P-int = 0.004). Conclusion(s): QoL deterioration persisted at 2 years after diagnosis with different trajectories by treatment received. ET, but not CT, had a major detrimental impact on C30-SumSc, especially in postmenopausal women. These findings highlight the need to properly select patients for adjuvant ET escalation.Funding Information
- Agence Nationale de la Recherche (10.13039/501100001665, ANR-10-COHO-0004)
- Susan G. Komen (10.13039/100009634, CCR17483507)
- Fondation ARC pour la Recherche sur le Cancer (10.13039/501100004097)
- CANTO-WORK programme labillisé
- Foundation Gustave Roussy
This publication has 17 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialJournal of Clinical Oncology, 2016
- Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body StudyJournal of Clinical Oncology, 2016
- Prospective Validation of a 21-Gene Expression Assay in Breast CancerThe New England Journal of Medicine, 2015
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerJournal of Clinical Oncology, 2012
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30Journal of Clinical Oncology, 2011
- Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose ChemotherapyJNCI Journal of the National Cancer Institute, 1998
- Life after breast cancer: understanding women's health-related quality of life and sexual functioning.Journal of Clinical Oncology, 1998
- Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancerThe Lancet, 1996
- Psychological distress after initial treatment for breast cancer: A comparison of partial and total mastectomyJournal of Clinical Epidemiology, 1989